WLF DEPOSITION OF FDA COMMISSIONER KESSLER IS JUSTIFIED BY "DIRECT" INVOLVEMENT WITH CME POLICY, FOUNDATION ARGUES; COURT RULING ON ISSUE EXPECTED IN MAY
This article was originally published in The Gray Sheet
Executive SummaryFDA Commissioner David Kessler's "direct, active role" in formulating the agency's draft policy on industry-sponsored continuing medical education makes him eligible for deposition, the Washington Legal Foundation says in a motion recently filed in the U.S. District Court for the District of Columbia as part of its suit against the policy. The motion says that "given Dr. Kessler's intimate personal involvement in the issues giving rise to this suit, WLF is entitled to question him regarding his knowledge of those issues."
You may also be interested in...
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.